Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 2Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Breast Neoplasms 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Stroke × Disulfides × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡